Nervosave Therapeutics

Nervosave Therapeutics is a Montpellier-based biotechnology company founded in 2021 by neuroscientist Nicolas Tricaud, PhD, and Cathy Beaumard [1, 5]. The company has developed a proprietary gene therapy platform designed to treat peripheral nerve disorders by utilizing AAV9 viral vectors to transduce Schwann cells [1, 7]. This platform leverages a novel delivery route adapted from standard regional anesthesia, allowing for localized and specific gene expression [4, 7]. By targeting these cells, the company aims to provide long-term therapeutic effects for various neuromuscular conditions [4, 7]. Its lead preclinical program, NVO-101, focuses on treating Charcot-Marie-Tooth disease type 1A (CMT1A), an inherited neurological disorder [1, 7].

Nervosave’s approach addresses significant medical needs by providing potential treatments for diseases that currently lack approved therapies, such as CMT1A, as well as neuropathic pain and diabetic neuropathy [2, 7, 8]. The company utilizes a well-controlled, minimally invasive injection technique that is widely recognized in medical practice, aiming to increase both safety and efficacy [7]. Having successfully completed preclinical proof-of-concept studies in rodent, monkey, and sheep models, as well as a pre-IND meeting with the FDA, Nervosave is currently working toward clinical validation for its pipeline [7, 8]. The company is actively seeking investment to support pivotal toxicity studies and advance its programs into human trials [7].